Matches in Wikidata for { <http://www.wikidata.org/entity/Q63571696> ?p ?o ?g. }
Showing items 1 to 36 of
36
with 100 items per page.
- Q63571696 description "clinical trial" @default.
- Q63571696 description "ensayu clínicu" @default.
- Q63571696 description "klinisch onderzoek" @default.
- Q63571696 description "клінічне випробування" @default.
- Q63571696 name "Sym021 Monotherapy and in Combination With Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas" @default.
- Q63571696 type Item @default.
- Q63571696 label "Sym021 Monotherapy and in Combination With Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas" @default.
- Q63571696 prefLabel "Sym021 Monotherapy and in Combination With Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas" @default.
- Q63571696 P1050 Q63571696-7C3A1934-4E00-4E96-82AF-D07762BA8C08 @default.
- Q63571696 P1132 Q63571696-25C21847-1BD6-4091-97FC-C413C28A745E @default.
- Q63571696 P1476 Q63571696-FB0960F3-DBA3-41AA-819E-1AA6ABD1A589 @default.
- Q63571696 P17 Q63571696-CC213CA6-E7DB-4A63-AECB-A03314C22CBC @default.
- Q63571696 P17 Q63571696-DBE5B8FD-4B31-4A88-B78C-B68441ECE192 @default.
- Q63571696 P2899 Q63571696-C3F4EB9E-BC9D-4EA0-BCF1-DCACBD9C475A @default.
- Q63571696 P3098 Q63571696-DA210AB2-63A4-456A-B67A-5C0C35C2D680 @default.
- Q63571696 P31 Q63571696-2D081626-575D-4D2A-89BA-8D1039311319 @default.
- Q63571696 P580 Q63571696-748AE679-A332-4A96-A553-9475CDB6E046 @default.
- Q63571696 P582 Q63571696-7FC5B36E-5D16-477D-9101-9BE560ADD28F @default.
- Q63571696 P6099 Q63571696-EE31D050-BA49-4F81-83BA-2893DFE56DD5 @default.
- Q63571696 P6153 Q63571696-5505C790-FE44-428C-9640-7F2272BBAA9D @default.
- Q63571696 P8363 Q63571696-C9F9937A-128C-425B-A8D0-BF68974E1F42 @default.
- Q63571696 P859 Q63571696-820A015F-8AE2-492A-9D2B-7E466E512A0A @default.
- Q63571696 P1050 Q208414 @default.
- Q63571696 P1132 "+102" @default.
- Q63571696 P1476 "A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy and in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas" @default.
- Q63571696 P17 Q16 @default.
- Q63571696 P17 Q30 @default.
- Q63571696 P2899 "+18" @default.
- Q63571696 P3098 "NCT03311412" @default.
- Q63571696 P31 Q30612 @default.
- Q63571696 P580 "2017-12-07T00:00:00Z" @default.
- Q63571696 P582 "2019-05-01T00:00:00Z" @default.
- Q63571696 P6099 Q5452194 @default.
- Q63571696 P6153 Q7896459 @default.
- Q63571696 P8363 Q78089383 @default.
- Q63571696 P859 Q7661403 @default.